Peptide Science Vermont

Peptide Science Vermont: A Comprehensive Overview of Research, Infrastructure, and Innovation

Peptide Science Vermont may be the second-least populous state in the United States, but the Green Mountain State has cultivated a surprisingly robust and impactful presence in the field of peptide science. Anchored by the research excellence of the University of Vermont (UVM) and supported by a growing infrastructure of proteomics facilities and specialized biotechnology companies, Vermont is making meaningful contributions to peptide-based research and therapeutic development. This article explores the multifaceted landscape of peptide science in Vermont, examining the key academic researchers, institutional resources, and commercial enterprises that are positioning the state as a quiet but significant player in this rapidly evolving field.

Academic Research and Institutional Leadership

The University of Vermont: A Hub of Peptide-Focused Inquiry

The University of Vermont serves as the undisputed center of peptide science in the state, housing multiple research groups whose work spans fundamental peptide chemistry, computational modeling, neuropeptide signaling, and therapeutic peptide design.

Computational Peptide Aggregation Research

Dr. Subhadra Thapa, a postdoctoral research scholar in the Department of Physics at UVM, is at the forefront of understanding peptide aggregation—a phenomenon critical to both neurodegenerative diseases and the practical challenges of peptide-based drug development. Thapa’s work explores the fundamental driving forces behind peptide aggregation, employing numerical approaches and machine learning to understand and predict peptide propensity toward aggregation. This computational work is essential for designing peptide therapeutics that remain stable and soluble, addressing one of the field’s most persistent challenges.

Neuropeptide Signaling and Behavioral Neuroscience

The laboratory of Professor Victor May, the Samuel W. Thayer Professor in the Department of Neurological Sciences, focuses on neurotransmitters, neuropeptides, and G protein-coupled receptors. May’s research has centered on pituitary adenylate cyclase activating polypeptide (PACAP), a highly conserved bioactive peptide that functions as both a neurotransmitter and neurotrophic peptide with a wide spectrum of physiological functions. PACAP shares receptor subtypes with VIP (vasoactive intestinal peptide), a related peptide family member, and binds specifically to PAC1 receptors.

May’s laboratory has made significant discoveries regarding PACAP’s role in stress and anxiety. The team has demonstrated that PACAP peptide infusions into specific amygdala-related nuclei facilitate anxiety-like behaviors, and that PAC1 receptor antagonists can attenuate stress-related responses. These findings have potentially important clinical implications, particularly given the observation that serum PACAP levels are elevated in female populations with post-traumatic stress disorder. The laboratory is now investigating the roles of estrogen in PACAP/PAC1 receptor expression and function, as well as PACAP’s involvement in pain pathways and migraine.

Peptide Mimetics and Bioorganic Chemistry

Professor Jose S. Madalengoitia leads a research group specializing in organic chemistry, bioorganic chemistry, and peptide mimetics. His laboratory’s work spans the synthesis of peptide mimics, proteomic approaches to identifying protein-protein interactions, and the development of methodology for combinatorial libraries. The group has developed a novel rearrangement called the 1,3-diaza-Claisen rearrangement, which has applications in the synthesis of guanidine natural products and peptide-like structures.

Selenium Biochemistry and Modified Peptide Science Vermont

Professor Robert J. Hondal’s research group investigates the redox chemistry and biology of sulfur and selenium, with a particular focus on selenocysteine—the 21st amino acid in the genetic code. The Hondal group has pioneered the incorporation of 2-thiohistidine, an analogue of the potential vitamin ergothioneine, into peptides. In a notable achievement, the team synthesized an analogue of the GHK-tripeptide—a peptide released from collagen after tissue injury and widely used in the cosmetic industry—replacing histidine with 2-thiohistidine. The resulting analogue demonstrated a remarkable gain in antioxidant function, comparable to vitamin C. This work opens new possibilities for biotechnological applications of modified peptides.

Bioanalytical Chemistry and Neuropeptides

Professor Yangguang Ou’s research in bioanalytical chemistry encompasses neurochemistry, neuropeptides, and neurotransmitter analysis using advanced electrochemical sensing techniques. This work provides critical analytical tools for understanding peptide function in the nervous system.

Norwich University: Peptide Research at the Military College

Beyond UVM, Norwich University—the nation’s oldest private military college—hosts peptide research through faculty like Emma Barrett. Barrett’s research interests include peptides with unique biological activities, specifically antioxidant peptides, the incorporation of non-natural amino acids into peptides, and the synthesis of novel amino acids. Her work focuses on designing peptide therapeutics with enhanced pharmacological properties.

Research Infrastructure and Core Facilities

Vermont Biomedical Research Network (VBRN) Proteomics Facility

A critical component of Vermont’s peptide science infrastructure is the VBRN Proteomics Facility, located in the Firestone Medical Research Building at UVM. Supported by INBRE funding (P20GM103449), the facility enables investigators to use state-of-the-art mass spectrometry-based techniques for proteomics experiments.

The facility provides mass spectrometry expertise for analyzing proteins and peptides, support for data analysis from proteomics measurements, and training in proteomics methods and experimental design. The facility works directly with over 100 UVM faculty, staff, and postdoctoral researchers, extending its services to institutions throughout Vermont. Consultations are available through facility directors Drs. Wai Lam and Bin Deng.

Vermont Genetics Network (VGN) Proteomics Core

The Vermont Genetics Network Proteomics Core, established in 2006, provides expertise and the latest proteomics technology to researchers at institutions within and outside Vermont. The core has been instrumental in supporting peptide and protein research across the state, helping investigators identify, characterize, and quantify target proteins in various biological and biomedical samples.

Commercial Landscape

New England Peptide, Inc.

New England Peptide, Inc., founded in 1998, is a Vermont-based manufacturer of peptides and antibodies for drug, vaccine, and diagnostic development applications. The company’s product portfolio includes amino acids, resins, assay reagents, monoclonal and polyclonal antibodies, albumin, and proteins. With annual sales between $5-9.9 million and 10-49 employees, New England Peptide represents a significant commercial presence in the state’s life sciences sector.

Atlantic Peptides

Atlantic Peptides is a custom peptide synthesizer that provides custom synthesized peptides for the production of antibodies, labeled peptides for assay development and high-throughput screening, and cGMP peptides for clinical trial experiments. The company supports research and in-process projects from pre-clinical toxicology studies through to early-stage clinical trials. Atlantic Peptides has offered the 29-chain amino acid Glucagon to scientific research laboratories and academic institutions for research pertaining to diabetes treatment and therapy.

Amino Acids and Nutritional Supplement Manufacturers

Vermont is also home to manufacturers of nutritional supplements that include amino acids, serving both the human and pet supplement markets. These companies, while not focused on therapeutic peptide development, contribute to the broader amino acid and peptide-related supply chain in the state.

Patents and Intellectual Property

The University of Vermont has been active in patenting peptide-related inventions. A notable example is the disclosure of a new polypeptide specifically detected in prostate cells, termed Novel Gene Expressed in Prostate (NGEP). UVM has also filed patents related to peptides and methods against diabetes, involving T cell receptor peptides for preventing or reducing the severity of the disease.

Therapeutic Applications and Clinical Research

Peptide therapeutics are gaining attention in Vermont’s clinical landscape. Peptides represent a unique class of drugs with characteristics of both small molecule drugs and larger proteins, used to treat a variety of diseases including cancer, diabetes, and immune disorders. The University of Vermont has been involved in clinical research on opioid-related disorders and HIV infections involving peptide-based approaches.

The Vermont Advantage

What makes Vermont’s peptide science ecosystem notable is its concentration of expertise within a relatively small geographic area. The University of Vermont’s Department of Chemistry covers all five traditional areas of chemical sciences while emphasizing cross-disciplinary work that brings together multiple disciplines. This collaborative environment enables peptide researchers to draw on expertise ranging from synthetic organic chemistry to computational biophysics and analytical neurochemistry.

The state’s research infrastructure, particularly the VBRN and VGN proteomics facilities, provides essential support for peptide characterization and analysis. These core facilities lower the barriers to entry for peptide research, enabling investigators across Vermont to access cutting-edge mass spectrometry technology.

Conclusion

Vermont may not be the first state that comes to mind when considering peptide science, but the Green Mountain State has cultivated a surprisingly rich and diverse peptide research ecosystem. From fundamental investigations into peptide aggregation and neuropeptide signaling at the University of Vermont to the commercialization of peptide synthesis through companies like New England Peptide and Atlantic Peptides, Vermont is making meaningful contributions to the field.

The state’s research strengths span computational modeling of peptide behavior, the synthesis of novel peptide mimetics and modified peptides, the investigation of neuropeptide function in stress and anxiety disorders, and the development of antioxidant peptides with cosmetic and therapeutic applications. Supported by robust proteomics infrastructure and a growing commercial sector, Vermont’s peptide science community continues to advance our understanding of these versatile molecules and their potential to address unmet medical needs.

As the field of peptide science continues to evolve, Vermont’s combination of academic excellence, collaborative research culture, and specialized commercial capabilities positions it to remain a quiet but significant contributor to this important area of biomedical research and development.